Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 58

1.

Development of an Influenza Rapid Diagnostic Kit Specific for the H7 Subtype.

Iwatsuki-Horimoto K, Shi J, Wang X, Sakai-Tagawa Y, Ito M, Murakami K, da Silva Lopes TJ, Nakaishi K, Yamayoshi S, Watabe S, Chen H, Kawaoka Y.

Front Microbiol. 2018 Jun 25;9:1346. doi: 10.3389/fmicb.2018.01346. eCollection 2018.

2.

The Marmoset as an Animal Model of Influenza: Infection With A(H1N1)pdm09 and Highly Pathogenic A(H5N1) Viruses via the Conventional or Tracheal Spray Route.

Iwatsuki-Horimoto K, Nakajima N, Kiso M, Takahashi K, Ito M, Inoue T, Horiuchi M, Okahara N, Sasaki E, Hasegawa H, Kawaoka Y.

Front Microbiol. 2018 May 9;9:844. doi: 10.3389/fmicb.2018.00844. eCollection 2018.

3.

Evaluation of the fusion partner cell line SPYMEG for obtaining human monoclonal antibodies against influenza B virus.

Soni P, Yasuhara A, Takenaga T, Iwatsuki-Horimoto K, Uraki R, Ito M, Sasaki T, Ikuta K, Yamayoshi S, Kawaoka Y.

J Vet Med Sci. 2018 Jun 29;80(6):1020-1024. doi: 10.1292/jvms.18-0146. Epub 2018 Apr 17.

4.

Experimental infection of Cynomolgus Macaques with highly pathogenic H5N1 influenza virus through the aerosol route.

Watanabe T, Iwatsuki-Horimoto K, Kiso M, Nakajima N, Takahashi K, Jose da Silva Lopes T, Ito M, Fukuyama S, Hasegawa H, Kawaoka Y.

Sci Rep. 2018 Mar 19;8(1):4801. doi: 10.1038/s41598-018-23022-0.

5.

Diversity of antigenic mutants of influenza A(H1N1)pdm09 virus escaped from human monoclonal antibodies.

Yasuhara A, Yamayoshi S, Soni P, Takenaga T, Kawakami C, Takashita E, Sakai-Tagawa Y, Uraki R, Ito M, Iwatsuki-Horimoto K, Sasaki T, Ikuta K, Yamada S, Kawaoka Y.

Sci Rep. 2017 Dec 18;7(1):17735. doi: 10.1038/s41598-017-17986-8.

6.

Syrian Hamster as an Animal Model for the Study of Human Influenza Virus Infection.

Iwatsuki-Horimoto K, Nakajima N, Ichiko Y, Sakai-Tagawa Y, Noda T, Hasegawa H, Kawaoka Y.

J Virol. 2018 Jan 30;92(4). pii: e01693-17. doi: 10.1128/JVI.01693-17. Print 2018 Feb 15.

7.

A Highly Pathogenic Avian H7N9 Influenza Virus Isolated from A Human Is Lethal in Some Ferrets Infected via Respiratory Droplets.

Imai M, Watanabe T, Kiso M, Nakajima N, Yamayoshi S, Iwatsuki-Horimoto K, Hatta M, Yamada S, Ito M, Sakai-Tagawa Y, Shirakura M, Takashita E, Fujisaki S, McBride R, Thompson AJ, Takahashi K, Maemura T, Mitake H, Chiba S, Zhong G, Fan S, Oishi K, Yasuhara A, Takada K, Nakao T, Fukuyama S, Yamashita M, Lopes TJS, Neumann G, Odagiri T, Watanabe S, Shu Y, Paulson JC, Hasegawa H, Kawaoka Y.

Cell Host Microbe. 2017 Nov 8;22(5):615-626.e8. doi: 10.1016/j.chom.2017.09.008. Epub 2017 Oct 19.

8.

Emergence of Oseltamivir-Resistant H7N9 Influenza Viruses in Immunosuppressed Cynomolgus Macaques.

Kiso M, Iwatsuki-Horimoto K, Yamayoshi S, Uraki R, Ito M, Nakajima N, Yamada S, Imai M, Kawakami E, Tomita Y, Fukuyama S, Itoh Y, Ogasawara K, Lopes TJS, Watanabe T, Moncla LH, Hasegawa H, Friedrich TC, Neumann G, Kawaoka Y.

J Infect Dis. 2017 Sep 1;216(5):582-593. doi: 10.1093/infdis/jix296.

PMID:
28931216
9.

Risk assessment of recent Egyptian H5N1 influenza viruses.

Arafa AS, Yamada S, Imai M, Watanabe T, Yamayoshi S, Iwatsuki-Horimoto K, Kiso M, Sakai-Tagawa Y, Ito M, Imamura T, Nakajima N, Takahashi K, Zhao D, Oishi K, Yasuhara A, Macken CA, Zhong G, Hanson AP, Fan S, Ping J, Hatta M, Lopes TJ, Suzuki Y, El-Husseiny M, Selim A, Hagag N, Soliman M, Neumann G, Hasegawa H, Kawaoka Y.

Sci Rep. 2016 Dec 6;6:38388. doi: 10.1038/srep38388.

10.

The Microminipig as an Animal Model for Influenza A Virus Infection.

Iwatsuki-Horimoto K, Nakajima N, Shibata M, Takahashi K, Sato Y, Kiso M, Yamayoshi S, Ito M, Enya S, Otake M, Kangawa A, da Silva Lopes TJ, Ito H, Hasegawa H, Kawaoka Y.

J Virol. 2017 Jan 3;91(2). pii: e01716-16. doi: 10.1128/JVI.01716-16. Print 2017 Jan 15.

11.

Selection of antigenically advanced variants of seasonal influenza viruses.

Li C, Hatta M, Burke DF, Ping J, Zhang Y, Ozawa M, Taft AS, Das SC, Hanson AP, Song J, Imai M, Wilker PR, Watanabe T, Watanabe S, Ito M, Iwatsuki-Horimoto K, Russell CA, James SL, Skepner E, Maher EA, Neumann G, Klimov AI, Kelso A, McCauley J, Wang D, Shu Y, Odagiri T, Tashiro M, Xu X, Wentworth DE, Katz JM, Cox NJ, Smith DJ, Kawaoka Y.

Nat Microbiol. 2016 May 23;1(6):16058. doi: 10.1038/nmicrobiol.2016.58.

12.

The ASK family kinases differentially mediate induction of type I interferon and apoptosis during the antiviral response.

Okazaki T, Higuchi M, Takeda K, Iwatsuki-Horimoto K, Kiso M, Miyagishi M, Yanai H, Kato A, Yoneyama M, Fujita T, Taniguchi T, Kawaoka Y, Ichijo H, Gotoh Y.

Sci Signal. 2015 Aug 4;8(388):ra78. doi: 10.1126/scisignal.aab1883. Erratum in: Sci Signal. 2017 May 30;10 (481):.

PMID:
26243192
13.

A Bivalent Vaccine Based on a PB2-Knockout Influenza Virus Protects Mice From Secondary Pneumococcal Pneumonia.

Uraki R, Piao Z, Akeda Y, Iwatsuki-Horimoto K, Kiso M, Ozawa M, Oishi K, Kawaoka Y.

J Infect Dis. 2015 Dec 15;212(12):1939-48. doi: 10.1093/infdis/jiv341. Epub 2015 Jun 29.

14.

Cats as a potential source of emerging influenza virus infections.

Horimoto T, Gen F, Murakami S, Iwatsuki-Horimoto K, Kato K, Hisasue M, Sakaguchi M, Nidom CA, Kawaoka Y.

Virol Sin. 2015 Jun;30(3):221-3. doi: 10.1007/s12250-015-3580-9. No abstract available.

PMID:
25953615
15.

A bivalent vaccine based on a replication-incompetent influenza virus protects against Streptococcus pneumoniae and influenza virus infection.

Katsura H, Piao Z, Iwatsuki-Horimoto K, Akeda Y, Watanabe S, Horimoto T, Oishi K, Kawaoka Y.

J Virol. 2014 Nov;88(22):13410-7. doi: 10.1128/JVI.01205-14. Epub 2014 Sep 10.

16.

Hemozoin as a novel adjuvant for inactivated whole virion influenza vaccine.

Uraki R, Das SC, Hatta M, Kiso M, Iwatsuki-Horimoto K, Ozawa M, Coban C, Ishii KJ, Kawaoka Y.

Vaccine. 2014 Sep 15;32(41):5295-300. doi: 10.1016/j.vaccine.2014.07.079. Epub 2014 Aug 6.

17.

Serological evidence of infection of dogs with human influenza viruses in Japan.

Horimoto T, Gen F, Murakami S, Iwatsuki-Horimoto K, Kato K, Akashi H, Hisasue M, Sakaguchi M, Kawaoka Y, Maeda K.

Vet Rec. 2014 Jan 25;174(4):96. doi: 10.1136/vr.101929. Epub 2013 Dec 11. No abstract available.

PMID:
24336761
18.

A replication-incompetent influenza virus bearing the HN glycoprotein of human parainfluenza virus as a bivalent vaccine.

Kobayashi H, Iwatsuki-Horimoto K, Kiso M, Uraki R, Ichiko Y, Takimoto T, Kawaoka Y.

Vaccine. 2013 Dec 16;31(52):6239-46. doi: 10.1016/j.vaccine.2013.10.029. Epub 2013 Oct 19.

PMID:
24144478
19.

Characterization of H7N9 influenza A viruses isolated from humans.

Watanabe T, Kiso M, Fukuyama S, Nakajima N, Imai M, Yamada S, Murakami S, Yamayoshi S, Iwatsuki-Horimoto K, Sakoda Y, Takashita E, McBride R, Noda T, Hatta M, Imai H, Zhao D, Kishida N, Shirakura M, de Vries RP, Shichinohe S, Okamatsu M, Tamura T, Tomita Y, Fujimoto N, Goto K, Katsura H, Kawakami E, Ishikawa I, Watanabe S, Ito M, Sakai-Tagawa Y, Sugita Y, Uraki R, Yamaji R, Eisfeld AJ, Zhong G, Fan S, Ping J, Maher EA, Hanson A, Uchida Y, Saito T, Ozawa M, Neumann G, Kida H, Odagiri T, Paulson JC, Hasegawa H, Tashiro M, Kawaoka Y.

Nature. 2013 Sep 26;501(7468):551-5. doi: 10.1038/nature12392. Epub 2013 Jul 10.

20.

A novel bivalent vaccine based on a PB2-knockout influenza virus protects mice from pandemic H1N1 and highly pathogenic H5N1 virus challenges.

Uraki R, Kiso M, Iwatsuki-Horimoto K, Fukuyama S, Takashita E, Ozawa M, Kawaoka Y.

J Virol. 2013 Jul;87(14):7874-81. doi: 10.1128/JVI.00076-13. Epub 2013 May 8.

21.

Virulence determinants of pandemic A(H1N1)2009 influenza virus in a mouse model.

Uraki R, Kiso M, Shinya K, Goto H, Takano R, Iwatsuki-Horimoto K, Takahashi K, Daniels RS, Hungnes O, Watanabe T, Kawaoka Y.

J Virol. 2013 Feb;87(4):2226-33. doi: 10.1128/JVI.01565-12. Epub 2012 Dec 5.

22.

Differences in cytokine production in human macrophages and in virulence in mice are attributable to the acidic polymerase protein of highly pathogenic influenza A virus subtype H5N1.

Sakabe S, Takano R, Nagamura-Inoue T, Yamashita N, Nidom CA, Quynh Le Mt, Iwatsuki-Horimoto K, Kawaoka Y.

J Infect Dis. 2013 Jan 15;207(2):262-71. doi: 10.1093/infdis/jis523. Epub 2012 Oct 4.

23.

A replication-incompetent virus possessing an uncleavable hemagglutinin as an influenza vaccine.

Katsura H, Iwatsuki-Horimoto K, Fukuyama S, Watanabe S, Sakabe S, Hatta Y, Murakami S, Shimojima M, Horimoto T, Kawaoka Y.

Vaccine. 2012 Sep 14;30(42):6027-33. doi: 10.1016/j.vaccine.2012.07.059. Epub 2012 Aug 3.

24.

Improved neutralizing antibody response in the second season after a single dose of pandemic (H1N1) 2009 influenza vaccine in HIV-1-positive adults.

Kikuchi T, Iwatsuki-Horimoto K, Adachi E, Koga M, Nakamura H, Hosoya N, Kawana-Tachikawa A, Koibuchi T, Miura T, Fujii T, Kawaoka Y, Iwamoto A.

Vaccine. 2012 Jun 6;30(26):3819-23. doi: 10.1016/j.vaccine.2012.03.083. Epub 2012 Apr 10.

PMID:
22504038
25.

Genetic characterization of H5N1 influenza viruses isolated from chickens in Indonesia in 2010.

Nidom CA, Yamada S, Nidom RV, Rahmawati K, Alamudi MY, Kholik, Indrasari S, Hayati RS, Iwatsuki Horimoto K, Kawaoka Y.

Virus Genes. 2012 Jun;44(3):459-65. doi: 10.1007/s11262-012-0722-0. Epub 2012 Feb 10.

26.

Unadjuvanted pandemic H1N1 influenza vaccine in HIV-1-infected adults.

Hatakeyama S, Iwatsuki-Horimoto K, Okamoto K, Nukui Y, Yata N, Fujita A, Inaba S, Yotsuyanagi H, Kawaoka Y.

Vaccine. 2011 Nov 15;29(49):9224-8. doi: 10.1016/j.vaccine.2011.09.106. Epub 2011 Oct 5.

27.

Avian-type receptor-binding ability can increase influenza virus pathogenicity in macaques.

Watanabe T, Shinya K, Watanabe S, Imai M, Hatta M, Li C, Wolter BF, Neumann G, Hanson A, Ozawa M, Yamada S, Imai H, Sakabe S, Takano R, Iwatsuki-Horimoto K, Kiso M, Ito M, Fukuyama S, Kawakami E, Gorai T, Simmons HA, Schenkman D, Brunner K, Capuano SV 3rd, Weinfurter JT, Nishio W, Maniwa Y, Igarashi T, Makino A, Travanty EA, Wang J, Kilander A, Dudman SG, Suresh M, Mason RJ, Hungnes O, Friedrich TC, Kawaoka Y.

J Virol. 2011 Dec;85(24):13195-203. doi: 10.1128/JVI.00859-11. Epub 2011 Sep 21.

28.

Mutation analysis of 2009 pandemic influenza A(H1N1) viruses collected in Japan during the peak phase of the pandemic.

Morlighem JÉ, Aoki S, Kishima M, Hanami M, Ogawa C, Jalloh A, Takahashi Y, Kawai Y, Saga S, Hayashi E, Ban T, Izumi S, Wada A, Mano M, Fukunaga M, Kijima Y, Shiomi M, Inoue K, Hata T, Koretsune Y, Kudo K, Himeno Y, Hirai A, Takahashi K, Sakai-Tagawa Y, Iwatsuki-Horimoto K, Kawaoka Y, Hayashizaki Y, Ishikawa T.

PLoS One. 2011 Apr 29;6(4):e18956. doi: 10.1371/journal.pone.0018956.

29.

Highly pathogenic avian influenza virus infection in feral raccoons, Japan.

Horimoto T, Maeda K, Murakami S, Kiso M, Iwatsuki-Horimoto K, Sashika M, Ito T, Suzuki K, Yokoyama M, Kawaoka Y.

Emerg Infect Dis. 2011 Apr;17(4):714-7. doi: 10.3201/eid1704.101604.

30.

Cytokine production by primary human macrophages infected with highly pathogenic H5N1 or pandemic H1N1 2009 influenza viruses.

Sakabe S, Iwatsuki-Horimoto K, Takano R, Nidom CA, Le Mt, Nagamura-Inoue T, Horimoto T, Yamashita N, Kawaoka Y.

J Gen Virol. 2011 Jun;92(Pt 6):1428-34. doi: 10.1099/vir.0.030346-0. Epub 2011 Mar 2.

31.

Seroprevalence of pandemic 2009 (H1N1) influenza A virus among schoolchildren and their parents in Tokyo, Japan.

Iwatsuki-Horimoto K, Horimoto T, Tamura D, Kiso M, Kawakami E, Hatakeyama S, Ebihara Y, Koibuchi T, Fujii T, Takahashi K, Shimojima M, Sakai-Tagawa Y, Ito M, Sakabe S, Iwasa A, Takahashi K, Ishii T, Gorai T, Tsuji K, Iwamoto A, Kawaoka Y.

Clin Vaccine Immunol. 2011 May;18(5):860-6. doi: 10.1128/CVI.00428-10. Epub 2011 Feb 23.

32.

Structure-based design of NS2 mutants for attenuated influenza A virus vaccines.

Akarsu H, Iwatsuki-Horimoto K, Noda T, Kawakami E, Katsura H, Baudin F, Horimoto T, Kawaoka Y.

Virus Res. 2011 Jan;155(1):240-8. doi: 10.1016/j.virusres.2010.10.014. Epub 2010 Oct 21.

33.

Influenza A (H5N1) viruses from pigs, Indonesia.

Nidom CA, Takano R, Yamada S, Sakai-Tagawa Y, Daulay S, Aswadi D, Suzuki T, Suzuki Y, Shinya K, Iwatsuki-Horimoto K, Muramoto Y, Kawaoka Y.

Emerg Infect Dis. 2010 Oct;16(10):1515-23. doi: 10.3201/eid1610.100508.

34.

The HA and NS genes of human H5N1 influenza A virus contribute to high virulence in ferrets.

Imai H, Shinya K, Takano R, Kiso M, Muramoto Y, Sakabe S, Murakami S, Ito M, Yamada S, Le MT, Nidom CA, Sakai-Tagawa Y, Takahashi K, Omori Y, Noda T, Shimojima M, Kakugawa S, Goto H, Iwatsuki-Horimoto K, Horimoto T, Kawaoka Y.

PLoS Pathog. 2010 Sep 16;6(9):e1001106. doi: 10.1371/journal.ppat.1001106.

35.

A cross-reactive neutralizing monoclonal antibody protects mice from H5N1 and pandemic (H1N1) 2009 virus infection.

Sakabe S, Iwatsuki-Horimoto K, Horimoto T, Nidom CA, Le Mt, Takano R, Kubota-Koketsu R, Okuno Y, Ozawa M, Kawaoka Y.

Antiviral Res. 2010 Dec;88(3):249-55. doi: 10.1016/j.antiviral.2010.09.007. Epub 2010 Sep 16.

36.

Induction of TNF-alpha in human macrophages by avian and human influenza viruses.

Monteerarat Y, Sakabe S, Ngamurulert S, Srichatraphimuk S, Jiamtom W, Chaichuen K, Thitithanyanont A, Permpikul P, Songserm T, Puthavathana P, Nidom CA, Mai le Q, Iwatsuki-Horimoto K, Kawaoka Y, Auewarakul P.

Arch Virol. 2010 Aug;155(8):1273-9. doi: 10.1007/s00705-010-0716-y. Epub 2010 Jun 9.

PMID:
20532927
37.

Significance of seasonal influenza viruses in the stool of pediatric patients.

Tamura D, Fujino M, Ozawa M, Iwatsuki-Horimoto K, Goto H, Sakai-Tagawa Y, Horimoto T, Nirasawa M, Kawaoka Y.

Pediatr Infect Dis J. 2010 Jun;29(6):578-9. doi: 10.1097/INF.0b013e3181dab225. No abstract available.

PMID:
20508482
38.

In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses.

Itoh Y, Shinya K, Kiso M, Watanabe T, Sakoda Y, Hatta M, Muramoto Y, Tamura D, Sakai-Tagawa Y, Noda T, Sakabe S, Imai M, Hatta Y, Watanabe S, Li C, Yamada S, Fujii K, Murakami S, Imai H, Kakugawa S, Ito M, Takano R, Iwatsuki-Horimoto K, Shimojima M, Horimoto T, Goto H, Takahashi K, Makino A, Ishigaki H, Nakayama M, Okamatsu M, Takahashi K, Warshauer D, Shult PA, Saito R, Suzuki H, Furuta Y, Yamashita M, Mitamura K, Nakano K, Nakamura M, Brockman-Schneider R, Mitamura H, Yamazaki M, Sugaya N, Suresh M, Ozawa M, Neumann G, Gern J, Kida H, Ogasawara K, Kawaoka Y.

Nature. 2009 Aug 20;460(7258):1021-5. doi: 10.1038/nature08260.

39.

Incorporation of influenza A virus genome segments does not absolutely require wild-type sequences.

Fujii K, Ozawa M, Iwatsuki-Horimoto K, Horimoto T, Kawaoka Y.

J Gen Virol. 2009 Jul;90(Pt 7):1734-40. doi: 10.1099/vir.0.010355-0. Epub 2009 Mar 18.

40.

Nucleotide sequence requirements at the 5' end of the influenza A virus M RNA segment for efficient virus replication.

Ozawa M, Maeda J, Iwatsuki-Horimoto K, Watanabe S, Goto H, Horimoto T, Kawaoka Y.

J Virol. 2009 Apr;83(7):3384-8. doi: 10.1128/JVI.02513-08. Epub 2009 Jan 21.

41.

Cross-clade protective immunity of H5N1 influenza vaccines in a mouse model.

Murakami S, Iwasa A, Iwatsuki-Horimoto K, Ito M, Kiso M, Kida H, Takada A, Nidom CA, Mai le Q, Yamada S, Imai H, Sakai-Tagawa Y, Kawaoka Y, Horimoto T.

Vaccine. 2008 Nov 25;26(50):6398-404. doi: 10.1016/j.vaccine.2008.08.053. Epub 2008 Sep 17.

42.

Growth determinants for H5N1 influenza vaccine seed viruses in MDCK cells.

Murakami S, Horimoto T, Mai le Q, Nidom CA, Chen H, Muramoto Y, Yamada S, Iwasa A, Iwatsuki-Horimoto K, Shimojima M, Iwata A, Kawaoka Y.

J Virol. 2008 Nov;82(21):10502-9. doi: 10.1128/JVI.00970-08. Epub 2008 Sep 3.

43.

Limited compatibility between the RNA polymerase components of influenza virus type A and B.

Iwatsuki-Horimoto K, Hatta Y, Hatta M, Muramoto Y, Chen H, Kawaoka Y, Horimoto T.

Virus Res. 2008 Jul;135(1):161-5. doi: 10.1016/j.virusres.2008.03.010. Epub 2008 May 2.

44.

A novel M cell-specific carbohydrate-targeted mucosal vaccine effectively induces antigen-specific immune responses.

Nochi T, Yuki Y, Matsumura A, Mejima M, Terahara K, Kim DY, Fukuyama S, Iwatsuki-Horimoto K, Kawaoka Y, Kohda T, Kozaki S, Igarashi O, Kiyono H.

J Exp Med. 2007 Nov 26;204(12):2789-96. Epub 2007 Nov 5.

45.

Enhanced growth of seed viruses for H5N1 influenza vaccines.

Horimoto T, Murakami S, Muramoto Y, Yamada S, Fujii K, Kiso M, Iwatsuki-Horimoto K, Kino Y, Kawaoka Y.

Virology. 2007 Sep 15;366(1):23-7. Epub 2007 Jul 24.

46.

Molecular characterization of the hemagglutinin and neuraminidase genes of H5N1 influenza A viruses isolated from poultry in Vietnam from 2004 to 2005.

Muramoto Y, Le TQ, Phuong LS, Nguyen T, Nguyen TH, Sakai-Tagawa Y, Iwatsuki-Horimoto K, Horimoto T, Kida H, Kawaoka Y.

J Vet Med Sci. 2006 May;68(5):527-31.

47.

The cytoplasmic tail of the influenza A virus M2 protein plays a role in viral assembly.

Iwatsuki-Horimoto K, Horimoto T, Noda T, Kiso M, Maeda J, Watanabe S, Muramoto Y, Fujii K, Kawaoka Y.

J Virol. 2006 Jun;80(11):5233-40.

48.

Hierarchy among viral RNA (vRNA) segments in their role in vRNA incorporation into influenza A virions.

Muramoto Y, Takada A, Fujii K, Noda T, Iwatsuki-Horimoto K, Watanabe S, Horimoto T, Kida H, Kawaoka Y.

J Virol. 2006 Mar;80(5):2318-25.

49.

The development and characterization of H5 influenza virus vaccines derived from a 2003 human isolate.

Horimoto T, Takada A, Fujii K, Goto H, Hatta M, Watanabe S, Iwatsuki-Horimoto K, Ito M, Tagawa-Sakai Y, Yamada S, Ito H, Ito T, Imai M, Itamura S, Odagiri T, Tashiro M, Lim W, Guan Y, Peiris M, Kawaoka Y.

Vaccine. 2006 Apr 24;24(17):3669-76. Epub 2005 Jul 21.

PMID:
16378663
50.

Generation of influenza A virus NS2 (NEP) mutants with an altered nuclear export signal sequence.

Iwatsuki-Horimoto K, Horimoto T, Fujii Y, Kawaoka Y.

J Virol. 2004 Sep;78(18):10149-55.

Supplemental Content

Loading ...
Support Center